This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…
Phase: PHASE1 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC